SEC Form 4 · accession 0001193125-26-267587
Aldeyra Therapeutics, Inc. · ALDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Darlene M Deptula-Hicks
Director
Period of report
Jun 9, 2026
Accepted (ET)
Jun 11, 2026 · 4:18 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001341235
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.72 | Jun 9, 2026 | A | 84,557 | A | — | Jun 8, 2036 | Common Stock | 84,557 | 84,557 | D |
| Stock Option (Right to Buy)F2 | $1.72 | Jun 9, 2026 | A | 9,756 | A | — | Jun 8, 2036 | Common Stock | 9,756 | 9,756 | D |
Explanation of responses
- F1The stock option is exercisable in equal annual installments over three years of continuous service to the Issuer after June 9, 2026.
- F2Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date.